Ronald Matricaria, William Mercer, Werner Schafer, Erich Mayer, Augustine Yee, Robert Brown, Daniel Von Hoff | GenomeWeb

Ronald Matricaria has been appointed to the board of directors of Invitrogen, the company announced last week. He replaces William Mercer, who is retiring. Matricaria was formerly the chairman and CEO of St. Jude Medical, where he increased revenues from $225 million to more than $1 billion. Prior to that, he worked for Eli Lilly, serving as CEO of Lilly subsidiary Cardiac Pacemakers and as executive vice president of the pharmaceutical division of Eli Lilly, in addition to other roles.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.